相关实验视频

Updated: Jun 15, 2026

A Mice Model of Chlorhexidine Gluconate-Induced Peritoneal Damage

A Mice Model of Chlorhexidine Gluconate-Induced Peritoneal Damage

Published on: April 28, 2022

奥利戈-富科伊丹在缓解腹腔透析相关纤维化的治疗潜力

Yu-Wei Chen^1,2,3,4, Mei-Yi Wu^2,3,4,5, Nai-Jen Huang⁶

¹Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.

|December 27, 2024

概括

奥利戈-富科伊丹可以预防由高葡萄糖透析溶液引起的腹纤维化. 这种棕色海藻提取物提供了一种潜在的新策略,可以在脏替代疗法期间保护腹膜.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
生物医学工程生物医学工程
细胞生物学细胞生物学

背景情况:

腹腔透析 (PD) 是一种至关重要的家庭替代疗法.
长期使用高葡萄糖PD溶液会导致腹损伤和纤维化,导致治疗失败.
了解PD相关的腹纤维化机制对于制定预防策略至关重要.

研究的目的:

研究由高葡萄糖PD溶液诱导的腹纤维化病理机制.
评估奥利戈-富科伊丹作为治疗PD相关腹膜纤维化病的治疗剂的潜力.

主要方法:

在实验室中使用人类中细胞MeT-5A的研究.
使用PD小鼠模型进行体内验证.
评估中细胞-中细胞过渡 (MMT) 标志物,活性氧物种 (ROS),炎症和腹纤维化.

主要成果:

高葡萄糖的PD溶液增加了MMT标记物 (N-cadherin,α-SMA),降低了catalase,并在MeT-5A细胞中增加了ROS.
患PD小鼠模型显示巨细胞流入增加和促炎性细胞因子 (IL-1β,MCP-1,TNF-α).
服用奥利戈-富科伊丹可以预防腹结和纤维化,减少MMT标志物,减轻炎症.

结论:

高葡萄糖的PD溶液通过氧化应激和炎症诱导腹纤维化.
奥利戈-富科伊丹显示出对与PD相关的腹纤维化有显著的保护作用.
奥利戈-富科伊丹是预防PD患者腹膜纤维化的一个有希望的候选者.

关键词:

在 MMT MMT 里面.纤维化纤维化介质细胞介质酶过渡.奥利戈-福科伊丹 (Oligo-fucoidan) 是一个非常古老的植物.腹膜透析是指腹膜透析.

更多相关视频

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

Detection of microRNA Expression in Peritoneal Membrane of Rats Using Quantitative Real-time PCR

Detection of microRNA Expression in Peritoneal Membrane of Rats Using Quantitative Real-time PCR

Published on: June 27, 2017

相关概念视频

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis

Patients with end-stage renal disease (ESRD) or those experiencing drug overdose often require extracorporeal methods to eliminate accumulated drugs and metabolites. Hemoperfusion, hemofiltration, and dialysis are the primary techniques to rapidly remove harmful substances without disrupting the patient's fluid and electrolyte balance. For those with compromised renal function, dosage adjustments of concurrent medications may be necessary during extracorporeal drug removal.Dialysis is a process...

Peritoneal Dialysis III: Nursing Management

Peritoneal Dialysis III: Nursing Management

Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...

Peritoneal Dialysis I: Introduction and Procedure

Peritoneal Dialysis I: Introduction and Procedure

Peritoneal dialysis (PD) is a procedure that facilitates the exchange of solutes, waste products, electrolytes, and excess fluid between the blood in the peritoneal capillaries and a dialysis solution introduced into the peritoneal cavity.Principles of Peritoneal Dialysis (PD)Diffusion: Waste products such as urea and electrolytes move from high concentrations in the blood to low concentrations in the dialysate across the peritoneal membrane. This mechanism is driven by the concentration...